Care Dx, Inc. CDNA
We take great care to ensure that the data presented and summarized in this overview for CareDx, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CDNA
View all-
Black Rock Inc. New York, NY5.29MShares$106 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.83MShares$96.8 Million0.0% of portfolio
-
Invesco Ltd. Atlanta, GA2.67MShares$53.4 Million0.01% of portfolio
-
State Street Corp Boston, MA2.48MShares$49.7 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl2.35MShares$47 Million0.45% of portfolio
-
Bamco Inc New York, NY2.19MShares$43.8 Million0.12% of portfolio
-
Ophir Asset Management Pty LTD1.62MShares$32.4 Million5.07% of portfolio
-
Hood River Capital Management LLC Palm Beach Gardens, FL1.58MShares$31.7 Million0.53% of portfolio
-
Fred Alger Management, LLC New York, NY1.43MShares$28.7 Million0.15% of portfolio
-
Gagnon Securities LLC1.42MShares$28.5 Million6.01% of portfolio
Latest Institutional Activity in CDNA
Top Purchases
Top Sells
About CDNA
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Insider Transactions at CDNA
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jul 08
2025
|
Michael Goldberg |
BUY
Grant, award, or other acquisition
|
Direct |
1,218
+0.78%
|
-
|
Jul 07
2025
|
Jeffrey Adam Novack Secretary and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
276
-0.23%
|
$4,968
$18.45 P/Share
|
Jul 07
2025
|
Peter Maag |
SELL
Open market or private sale
|
Direct |
10,000
-3.14%
|
$180,000
$18.58 P/Share
|
Jun 18
2025
|
Hannah Valantine |
SELL
Open market or private sale
|
Direct |
10,570
-21.33%
|
$200,830
$19.16 P/Share
|
Jun 17
2025
|
Peter Maag |
SELL
Open market or private sale
|
Direct |
10,000
-3.04%
|
$190,000
$19.24 P/Share
|
Jun 13
2025
|
Michael Goldberg |
BUY
Grant, award, or other acquisition
|
Direct |
12,103
+7.33%
|
-
|
Jun 13
2025
|
Fred E Cohen |
BUY
Grant, award, or other acquisition
|
Direct |
12,103
+7.23%
|
-
|
Jun 13
2025
|
Arthur A Torres |
BUY
Grant, award, or other acquisition
|
Direct |
12,103
+19.73%
|
-
|
Jun 13
2025
|
Christine Cournoyer |
BUY
Grant, award, or other acquisition
|
Direct |
12,103
+19.76%
|
-
|
Jun 13
2025
|
Hannah Valantine |
BUY
Grant, award, or other acquisition
|
Direct |
12,103
+19.63%
|
-
|
Jun 13
2025
|
George Bickerstaff |
BUY
Grant, award, or other acquisition
|
Direct |
12,103
+9.51%
|
-
|
Jun 13
2025
|
Richard Bryan Riggsbee |
BUY
Grant, award, or other acquisition
|
Direct |
12,103
+29.08%
|
-
|
Jun 13
2025
|
Peter Maag |
BUY
Grant, award, or other acquisition
|
Direct |
12,103
+3.55%
|
-
|
Jun 11
2025
|
William A Hagstrom |
SELL
Open market or private sale
|
Direct |
19,391
-26.43%
|
$368,429
$19.9 P/Share
|
Jun 11
2025
|
William A Hagstrom |
BUY
Exercise of conversion of derivative security
|
Direct |
19,391
+11.75%
|
$213,301
$11.35 P/Share
|
Jun 06
2025
|
Jeffrey Adam Novack Secretary and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
2,583
-2.13%
|
$49,077
$19.52 P/Share
|
May 28
2025
|
William A Hagstrom |
SELL
Open market or private sale
|
Direct |
30,000
-35.72%
|
$510,000
$17.45 P/Share
|
May 28
2025
|
William A Hagstrom |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+10.32%
|
$180,000
$6.25 P/Share
|
May 27
2025
|
Abhishek Jain Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,982
-0.6%
|
$33,694
$17.63 P/Share
|
May 12
2025
|
Christine Cournoyer |
SELL
Open market or private sale
|
Direct |
29,136
-44.02%
|
$437,040
$15.96 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 680K shares |
---|---|
Exercise of conversion of derivative security | 179K shares |
Open market or private sale | 311K shares |
---|---|
Payment of exercise price or tax liability | 132K shares |